JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

Autor: DeFronzo, Ralph A

8 záznamů v Medvik Filtry

Článek

Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases

Handelsman, Yehuda
Autor Handelsman, Yehuda Metabolic Institute of America, Tarzana, CA, USA. Electronic address: yhandelsman@gmail.com
Butler, Javed
Autor Butler, Javed Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, TX, USA University of Mississippi Medical Center, Jackson, MS, USA
Bakris, George L
Autor Bakris, George L American Heart Association Comprehensive Hypertension Center, University of Chicago Pritzker School of Medicine, Chicago, IL, USA
DeFronzo, Ralph A
Autor DeFronzo, Ralph A University of Texas Health Science Center at San Antonio, Texas Diabetes Institute, San Antonio, TX, USA
Fonarow, Gregg C
Autor Fonarow, Gregg C Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-UCLA Medical Center, UCLA Preventative Cardiology Program, UCLA Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Green, Jennifer B
Autor Green, Jennifer B Division of Endocrinology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Grunberger, George
Autor Grunberger, George Grunberger Diabetes Institute, Internal Medicine and Molecular Medicine & Genetics, Wayne State University School of Medicine, Department of Internal Medicine, Oakland University William Beaumont School of Medicine, Bloomfield Hills, MI, USA Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
Januzzi, James L
Autor Januzzi, James L Cardiology Division, Harvard Medical School, Massachusetts General Hospital, Cardiometabolic Trials, Baim Institute, Boston, MA, USA
Klein, Samuel
Autor Klein, Samuel Washington University School of Medicine, Saint Louis, MO, USA Sansum Diabetes Research Institute, Santa Barbara, CA, USA
Kushner, Pamela R
Autor Kushner, Pamela R University of California Medical Center, Kushner Wellness Center, Long Beach, CA, USA

Journal of diabetes and its complications. 2023 ; 37 (2) : 108389. [pub] 20230103

J. Diabetes Complicat.
ISSN 1873-460X
Medvik
Zdroj

Increasing rates of obesity and diabetes have driven corresponding increases in related cardiorenal and metabolic diseases. In many patients, these conditions occur together, further increasing morbidity and mortality risks to the individual. Yet all too often, the risk factors for these disorders are not addressed promptly in clinical practice, leading to irreversible pathologic progression. To address this gap, we convened a Task Force of experts in cardiology, nephrology, endocrinology, and primary care to develop recommendations for early identification and intervention in obesity, diabetes, and other cardiorenal and metabolic diseases. The recommendations include screening and diagnosis, early interventions with lifestyle, and when and how to implement medical therapies. These recommendations are organized into primary and secondary prevention along the continuum from obesity through the metabolic syndrome, prediabetes, diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), atherosclerotic cardiovascular disease (ASCVD) and atrial fibrillation, chronic kidney disease (CKD), and heart failure (HF). The goal of early and intensive intervention is primary prevention of comorbidities or secondary prevention to decrease further worsening of disease and reduce morbidity and mortality. These efforts will reduce clinical inertia and may improve patients' well-being and adherence.

MeSH
diabetes mellitus * MeSH
hypertenze * MeSH
kardiovaskulární nemoci * komplikace epidemiologie prevence a kontrola MeSH
komorbidita MeSH
lidé MeSH
obezita terapie MeSH
rizikové faktory MeSH
Check Tag
lidé MeSH
Publikační typ
časopisecké články MeSH
přehledy MeSH

Článek

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Journal of diabetes and its complications. 2022 ; 36 (2) : 108101. [pub] 20211207

J. Diabetes Complicat.
ISSN 1873-460X
Medvik
Zdroj

Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM.